It is recommended not to use Regpara in pregnant women or in women who may possibly be pregnant. The drug should be used in such patients only if the anticipated therapeutic benefits outweigh the potential risks associated with the treatment. The safety of Regpara during pregnancy has not been established. Hypocalcaemia, suppressed weight gain and decreased food consumption in mothers, as well as decreased weight in fetuses were observed in animal studies (using rats and rabbits). Furthermore, Regpara was reported to be transferred through the placenta in animal studies (using rats and rabbits).
Treatment with Regpara should be avoided in nursing mothers. When the use is necessary in such women, breastfeeding should be discontinued. In animal studies (using rats), Regpara was reported to be transferred into milk. Furthermore, suppressed weight gain was observed in newborns on breastfeeding.